Viking Therapeutics Shares Fall Nearly 3% Overnight After Wider Q3 Loss
Viking Therapeutics shares fell nearly 3% overnight after the company posted a wider-than-expected quarterly loss. CEO Brian Lian said the obesity-drug launch timeline is more than two years away.